Omeros submitted an application to the FDA seeking orphan-drug designation for OMS721, an investigational drug for atypical hemolytic uremic syndrome. The drug, which targets the lectin pathway of the complement system, is formulated for self-administration through subcutaneous injection. The firm plans to apply for a similar designation in Europe and to initiate clinical studies in the summer.

Related Summaries